Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH.

Mol Cancer Ther. 2011 Dec;10(12):2298-308. doi: 10.1158/1535-7163.MCT-11-0264. Epub 2011 Sep 16.

2.

c-Met is a marker of pancreatic cancer stem cells and therapeutic target.

Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, Pasca di Magliano M, Simeone DM.

Gastroenterology. 2011 Dec;141(6):2218-2227.e5. doi: 10.1053/j.gastro.2011.08.009. Epub 2011 Aug 22.

PMID:
21864475
3.

TGF-β/TGF-β receptor system and its role in physiological and pathological conditions.

Santibañez JF, Quintanilla M, Bernabeu C.

Clin Sci (Lond). 2011 Sep;121(6):233-51. doi: 10.1042/CS20110086. Review.

PMID:
21615335
4.

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.

You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, Aftab DT, McDonald DM.

Cancer Res. 2011 Jul 15;71(14):4758-68. doi: 10.1158/0008-5472.CAN-10-2527. Epub 2011 May 25.

5.

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R.

J Clin Oncol. 2011 Jul 1;29(19):2660-6. doi: 10.1200/JCO.2010.32.4145. Epub 2011 May 23.

6.

HGF-independent potentiation of EGFR action by c-Met.

Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM.

Oncogene. 2011 Aug 18;30(33):3625-35. doi: 10.1038/onc.2011.84. Epub 2011 Mar 21.

7.

GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood-brain barrier.

Cullen M, Elzarrad MK, Seaman S, Zudaire E, Stevens J, Yang MY, Li X, Chaudhary A, Xu L, Hilton MB, Logsdon D, Hsiao E, Stein EV, Cuttitta F, Haines DC, Nagashima K, Tessarollo L, St Croix B.

Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5759-64. doi: 10.1073/pnas.1017192108. Epub 2011 Mar 18.

8.

The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model.

Sampson ER, Martin BA, Morris AE, Xie C, Schwarz EM, O'Keefe RJ, Rosier RN.

J Bone Miner Res. 2011 Jun;26(6):1283-94. doi: 10.1002/jbmr.336.

9.

Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.

Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Jänne PA, Engelman JA.

Cancer Res. 2011 Feb 1;71(3):1081-91. doi: 10.1158/0008-5472.CAN-10-1623. Epub 2011 Jan 25.

10.

MET signalling: principles and functions in development, organ regeneration and cancer.

Trusolino L, Bertotti A, Comoglio PM.

Nat Rev Mol Cell Biol. 2010 Dec;11(12):834-48. doi: 10.1038/nrm3012. Review.

11.

Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis.

Chun MG, Mao JH, Chiu CW, Balmain A, Hanahan D.

Proc Natl Acad Sci U S A. 2010 Oct 5;107(40):17268-73. doi: 10.1073/pnas.1012705107. Epub 2010 Sep 20.

12.

Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells.

Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV.

Oncogene. 2010 May 6;29(18):2616-27. doi: 10.1038/onc.2010.16. Epub 2010 Feb 15.

13.

Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.

McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J.

Cancer Res. 2010 Feb 15;70(4):1625-34. doi: 10.1158/0008-5472.CAN-09-3620. Epub 2010 Feb 2.

14.

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.

Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackin C, Lorens JB.

Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9. doi: 10.1073/pnas.0909333107. Epub 2009 Dec 28.

15.

E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.

Nakagawa T, Tohyama O, Yamaguchi A, Matsushima T, Takahashi K, Funasaka S, Shirotori S, Asada M, Obaishi H.

Cancer Sci. 2010 Jan;101(1):210-5. doi: 10.1111/j.1349-7006.2009.01343.x. Epub 2009 Sep 2.

16.

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH.

Cancer Res. 2009 Oct 15;69(20):8009-16. doi: 10.1158/0008-5472.CAN-08-4889. Epub 2009 Oct 6.

17.

Crosstalk in Met receptor oncogenesis.

Lai AZ, Abella JV, Park M.

Trends Cell Biol. 2009 Oct;19(10):542-51. doi: 10.1016/j.tcb.2009.07.002. Epub 2009 Sep 14. Review.

PMID:
19758803
18.

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer.

Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, Germain D, Omeroglu A, Cardiff RD, Hallett M, Park M.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12903-8. doi: 10.1073/pnas.0810402106. Epub 2009 Jul 17.

19.

Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.

Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA, Vande Woude GF.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12909-14. doi: 10.1073/pnas.0810403106. Epub 2009 Jun 30.

20.

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

Timofeevski SL, McTigue MA, Ryan K, Cui J, Zou HY, Zhu JX, Chau F, Alton G, Karlicek S, Christensen JG, Murray BW.

Biochemistry. 2009 Jun 16;48(23):5339-49. doi: 10.1021/bi900438w.

PMID:
19459657

Supplemental Content

Support Center